Skip to main content
Log in

Osimertinib

Acquired drug resistance: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Yang Z, et al. Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient. Targeted Oncology 14: 369-374, No. 4, Aug 2019. Available from: URL: http://doi.org/10.1007/s11523-019-00652-6 - China

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Osimertinib. Reactions Weekly 1769, 336 (2019). https://doi.org/10.1007/s40278-019-67350-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-67350-x

Navigation